- The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Biotechnology industry average. The net income has decreased by 3.2% when compared to the same quarter one year ago, dropping from -$1.59 million to -$1.64 million.
- Net operating cash flow has declined marginally to -$1.58 million or 0.18% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- OGEN's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 39.05%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ORAGENICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- The gross profit margin for ORAGENICS INC is rather high; currently it is at 65.58%. Regardless of OGEN's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, OGEN's net profit margin of -763.25% significantly underperformed when compared to the industry average.
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices traded up today with the Dow Jones Industrial Average ( ^DJI) trading up 81 points (0.5%) at 16,920 as of Tuesday, Aug. 19, 2014, 4:20 PM ET. The NYSE advances/declines ratio sits at 1,954 issues advancing vs. 1,082 declining with 162 unchanged. The Drugs industry as a whole was unchanged today versus the S&P 500, which was up 0.5%. Top gainers within the Drugs industry included Cellectar Biosciences ( CLRB), up 1.6%, China Pharma ( CPHI), up 2.7%, Oragenics ( OGEN), up 2.4%, MediciNova ( MNOV), up 5.6% and Celator Pharmaceuticals ( CPXX), up 2.7%. TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today: Oragenics ( OGEN) is one of the companies that pushed the Drugs industry higher today. Oragenics was up $0.04 (2.4%) to $1.70 on light volume. Throughout the day, 2,600 shares of Oragenics exchanged hands as compared to its average daily volume of 20,400 shares. The stock ranged in a price between $1.70-$1.73 after having opened the day at $1.72 as compared to the previous trading day's close of $1.66. Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. Oragenics has a market cap of $62.6 million and is part of the health care sector. Shares are down 40.9% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates Oragenics a buy, no analysts rate it a sell, and none rate it a hold. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. TheStreet Ratings rates Oragenics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Highlights from TheStreet Ratings analysis on OGEN go as follows: